Externally Partnered Pipeline
Our partnered pipeline includes drug candidates that we have out licensed to leading pharmaceutical and biotechnology companies, including Boehringer Ingelheim and Kite Pharma.
Our partners are developing one or more drug candidates that we discovered using our OGAP® platform.
Our partners are developing one or more drug candidates that we discovered using our OGAP® platform.
Program |
Program Summary |
Indications |
Molecule Class |
OBT620 |
A DLL3/CD3 bispecific molecule to treat patients with small cell lung cancer and other neuroendocrine tumors that are positive for DLL3. Currently in phase I clinical trial. |
SCLC and neuroendocrine tumors |
CD3 bispecific |
OBT624 |
A bispecific molecule to treat patients with advanced solid tumors. |
Advanced solid tumors |
CD3 bispecific |
OBT551 |
Undisclosed molecule in pre-clinical development. |
Undisclosed |
Undisclosed |
Four programs |
OBT and Boehringer Ingelheim (BI) are collaborating to discover and validate novel selective tumor targets for BI’s unique T-cell engager, cancer vaccine and oncolytic virus platforms, enabled by OBTs OGAP® discovery. Four further programs enabled by OBTs OGAP® discovery platform are also undergoing validation. |
Solid tumors |
Undisclosed |
OBT700 |
A novel, first-in-class, immune checkpoint receptor agonist discovered and developed by OBT. |
Solid tumors |
IO mAB |
OBT035 |
An ADC specifically targeting ‘cold’ tumors that cannot be treated with check point inhibitors. |
"Cold" and solid tumors |
ADC |
OBT227 |
Novel ADC with strong cancer biology overexpressed in multiple solid tumors. |
Solid tumors |
ADC |
OBT417 |
Novel ADC with strong cancer biology overexpressed in multiple solid tumors. |
Solid tumors |
ADC |
Five programs |
OBT and ImmunoGen are collaborating to develop novel antibidy drug conjugates coupling targets discovered using OBT's OGAP® discovery platform, with ImmunoGen's ADC linker-payload technology. |
Hematological and solid tumors |
ADC |
Two programs |
Through this collaboration, OBT will validate up to five novel oncology drug targets, previously identified using OBT’s OGAP® discovery platform, and generate antibodies against these. Kite and Gilead will have the exclusive right to develop and commercialize therapies based on these targets or antibodies. |
Hematological and solid tumors |
CAR-T therapy |
IO mAB: Immuno-oncology monoclonal antibody; ADC: Antibody drug conjugate; CAR-T therapy: Chimeric antigen receptor T cell therapy